Searchable abstracts of presentations at key conferences in endocrinology

ea0063p946 | Diabetes, Obesity and Metabolism 3 | ECE2019

Screening of abnormal glucose metabolism in cystic fibrosis could there be a place for DPP-4 inhibitors in early stages?

Peris Begona Pla , Sanchez Clara Marijuan , Moreno Nerea Aguirre , Alday Inigo Hernando , Blanco Sara Jimenez , Nunez Miguel Sampedro , Moreno Rosa Giron , Azpiroz Monica Marazuela , Martin Alfonso Arranz

Introduction: Abnormal glucose metabolism (AGM) is the most common extra-pulmonary comorbidity in people with cystic fibrosis (CF) and has a high negative impact on the underlying disease. Elevated postprandial glucose level is usually the first manifestation, which is traditionally detected by 75-gram oral glucose tolerance test (OGTT). The aim of this study was to evaluate glycemic pattern during continuous glucose monitoring (CGM) in patients with impaired glucose metabolis...

ea0063p1216 | Thyroid 3 | ECE2019

Real-life experience with lenvatinib in iodine-refractory thyroid cancer in a terciary hospital

Sanchez Clara Marijuan , Peris Begona Pla , Moreno Nerea Aguirre , Alday Inigo Hernando , Blanco Sara Jimenez , Azpiroz Monica Marazuela , Vargas Marcos Lahera

Introduction: Lenvatinib is an oral tyrosine kinase inhibitor (TKI) used for treatment of progressive, clinically significant or symptomatic disease in patients with iodine-refractory differentiated thyroid cancer (DTC).Objective: To describe our clinical experience with lenvatinib in patients with iodine-refractory differentiated thyroid cancer.Methods: Restrospective cohort study of patients with iodine-refractory differentiated ...

ea0056p740 | Growth hormone IGF axis - basic | ECE2018

GH replacement therapy (GHRT) in adult patients with GH deficiency (GHD): a long term follow up

Peris Begona Pla , Ramos-Levi Ana Maria , Marijuan Clara , Fernandez Elena , Aguirre Nerea , Mosse Alexia , Jimenez Sara , Hernando Inigo , Vargas Marcos Lahera , Azpiroz Monica Marazuela

Introduction: GH deficiency (GHD) leads to altered body composition, lipid metabolism and quality of life, and is also associated to an increased cardiovascular morbidity and mortality. The aim of this study was to evaluate long-term changes after treatment with GH replacement therapy (GHRT).Methods: We retrospectively reviewed adult patients with GHD in our clinic who were treated with GHRT. We evaluated demographic (etiology, age, dose), anthropometric...

ea0049ep1072 | Pituitary - Clinical | ECE2017

Risk factors for progression of the surgical remnant of non-functioning pituitary adenomas in patients treated with dopamine agonists

Gonzalez Elena Fernandez , Nunez Miguel Sampedro , Levi Ana Ramos , Caon Ana Rabe , Hughet Isabel , Moreno Nerea Aguirre , Sanchez Clara Marijuan , Peris Begona Pla , Nieto Angeles Maillo , Andres Alicia Vicuna , Flores Pedro Martinez , Azpiroz Monica Marazuela

Introduction: Surgery is the treatment of choice for non-functioning pituitary adenomas (NFPA), but remnants are frequently observed. Management of these remnants include observation (OBS), radiotherapy (RT) and/or dopamine agonist (DA) therapy. In this study, we evaluate the progression-free survival (PFS) of NFPA with postoperative remnant and the potential factors involved.Methods: We performed a single-center ambispective study of a cohort of 72 pati...

ea0056p1166 | Thyroid cancer | ECE2018

Descriptive analysis of papillary thyroid microcarcinomas in a single-center

Gonzalez Elena Fernandez , Moreno Isabel Huguet , Munoz Jose Luis , Moreno Nerea Aguirre , Peris Begona Pla , Sanchez Clara Marijuan , Castro Marta Araujo , Ramos-Levi Ana , Azpiroz Monica Marazuela , Ramirez Manuel Luque , Vargas Marcos Lahera

Introduction: The incidence of papillary thyroid microcarcinomas (MPT, max diameter≤10 mm) has increased in recent years. Most have a very good prognosis but some have growth during follow-up, lymph node and / or distant metastases.Material and methods: We performed a single-center, retrospective cohort study, n=114 patients (86% women, average age 48.3 years), diagnosed with MPT between 1998 and 2012. Risk stratification system (ATA 2015): 10 high...